Thomas Antonsson
BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O 43150, Sweden
Goeteborg, O 43150, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction".
Journal: Journal of medicinal chemistry
Published: October 03, 2022
Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: August 30, 2022
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
Journal: Journal of medicinal chemistry
Published: August 25, 2022
Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function.
Journal: The Journal of biological chemistry
Published: October 04, 2019
Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
Journal: Bioorganic & medicinal chemistry letters
Published: December 17, 2018
Structural and functional characterization of a specific antidote for ticagrelor.
Journal: Blood
Published: January 16, 2015
Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations.
Journal: Bioorganic & medicinal chemistry letters
Published: January 17, 2014
Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
Journal: Journal of medicinal chemistry
Published: August 01, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026